INTRO

INTRO
KOR
CHN

GemVax & KAEL

GemVax & KAEL is dedicated to healthy lives and improved quality of human life

Vision

GemVax, the biopharmaceutical company, has been actively pursuing research and development of novel therapeutic drugs exhibiting superior safety and efficacy based on the proven technologies demonstrated from the development of world’s first-in-class pancreatic cancer immunotherapeutic peptide GV1001™.

R&D Network

GemVax has established close R&D networks with its own research centers(GemVax & KAEL R&D center and Samsung Pharm. R&D center) as well as international or domestic hospital and university research groups (UCLA, Hanyang University, Ajou University, etc.).